These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1697421)

  • 1. [Advances in the treatment of advanced colorectal cancer].
    Díaz-Rubio E
    Rev Clin Esp; 1990 Apr; 186(6):292-300. PubMed ID: 1697421
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sequential therapy with methotrexate and 5-fluorouracil in patients with advanced colorectal cancer pretreated with 5-fluorouracil plus folinic acid].
    Paoletti G; Di Lauro L; Gionfra T; Venturo I; Belli F; Squilloni E; Mariotti S; Fioretti G; Gemini M; Tersigni R; Lopez M
    Clin Ter; 1998; 149(2):105-8. PubMed ID: 9780473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Systemic chemotherapy in metastatic colorectal adenocarcinomas].
    Bécouarn Y; Brunet R; Ravaud A; Bussières E; Lagarde P
    Gastroenterol Clin Biol; 1992; 16(2):166-76. PubMed ID: 1568545
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of advanced colorectal cancer.
    Bleiberg H
    Anticancer Res; 1989; 9(4):1013-5. PubMed ID: 2683986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced colorectal cancer.
    Abbruzzese JL; Levin B
    Hematol Oncol Clin North Am; 1989 Mar; 3(1):135-53. PubMed ID: 2465291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy.
    Rosa DD; Ismael GF; de Azambuja E; Braga S; Cardoso F; Bleiberg H
    J Clin Oncol; 2006 Nov; 24(32):5176-7; author reply 5177. PubMed ID: 17093286
    [No Abstract]   [Full Text] [Related]  

  • 7. [Colorectal carcinoma--approval of eloxatine in adjuvant therapy--better chances for recovery].
    Krankenpfl J; 2004; 42(7-10):234. PubMed ID: 15675396
    [No Abstract]   [Full Text] [Related]  

  • 8. Ineffectiveness of sequential high dose methotrexate and 5-fluorouracil combined with epirubicin (FEMTX regimen) as a salvage therapy in advanced colorectal cancers and other gastrointestinal tumors.
    Adenis A; Leriche N; Pion JM; Vanlemmens L; Bonneterre J
    Anticancer Res; 1996; 16(4A):2063-7. PubMed ID: 8712743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of antifolates and folates on the antineoplastic action of fluoropyrimidines].
    Graczyk J
    Postepy Hig Med Dosw; 1992; 46(2):143-58. PubMed ID: 1470578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer.
    Schrag D; Weiser M; Schattner M; Shia J; Akhurst T
    J Clin Oncol; 2005 Mar; 23(9):1799-802. PubMed ID: 15774773
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapeutic strategies in colorectal cancer].
    Flieger D; Keller R; Fischbach W
    Dtsch Med Wochenschr; 2003 Sep; 128(37):1902-7. PubMed ID: 12970825
    [No Abstract]   [Full Text] [Related]  

  • 12. Biomodulation of 5-fluorouracil with antifolates.
    Bertino JR
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical modulation of fluorouracil with high dose methotrexate or folinic acid in advanced colorectal cancer patients. Gruppo Oncologico dell' Italia Meridionale (GOIM).
    Colucci G; Maiello E; Leo S; Giuliani F; Pedicini A; Pezzella G; Valori V; Galetta D; Contillo A; Prete F
    Anticancer Res; 1994; 14(5B):2157-62. PubMed ID: 7840516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer.
    Paradiso A; Simone G; Lena MD; Leone B; Vallejo C; Lacava J; Dellapasqua S; Daidone MG; Costa A
    Br J Cancer; 2001 Mar; 84(5):651-8. PubMed ID: 11237386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer.
    Zelek L; Piedbois P; Buyse M
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):417-25. PubMed ID: 12647985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-fluorouracil modulation in the chemotherapy of colorectal cancer.
    Codacci-Pisanelli G; Franchi F
    Ital J Gastroenterol; 1994 Sep; 26(7):369-76. PubMed ID: 7529067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of oxaliplatin: an active platinum agent in colorectal cancer.
    Cassidy J
    Int J Clin Pract; 2000; 54(6):399-402. PubMed ID: 11092115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
    Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
    In Vivo; 2005; 19(6):1077-80. PubMed ID: 16277025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiblastic treatment in metastatic colorectal cancer].
    Mustacchi G; Milani S
    Ann Ital Chir; 1992; 63(3):333-6. PubMed ID: 1280019
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.